{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:03:05Z","timestamp":1793289785621,"version":"4.5.0"},"reference-count":91,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In the past decade, the medical management of people with cystic fibrosis (pwCF) has changed with the development of small molecules that partially restore the function of the defective CF transmembrane conductance regulator (CFTR) protein and are called CFTR modulators. Ivacaftor (IVA), a CFTR potentiator with a large effect on epithelial ion transport, was the first modulator approved in pwCF carrying gating mutations. Because IVA was unable to restore sufficient CFTR function in pwCF with other mutations, two CFTR correctors (lumacaftor and tezacaftor) were developed and used in combination with IVA in pwCF homozygous for F508del, the most common CFTR variant. However, LUM\/IVA and TEZ\/IVA were only moderately effective in F508del homozygous pwCF and had no efficacy in those with F508del and minimal function mutations. Elexacaftor, a second-generation corrector, was thus developed and combined to tezacaftor and ivacaftor (ELX\/TEZ\/IVA) to target pwCF with at least one F508del variant, corresponding to approximately 85% of pwCF. Both IVA and ELX\/TEZ\/IVA are considered highly effective modulator therapies (HEMTs) in eligible pwCF and are now approved for nearly 90% of the CF population over 6 years of age. HEMTs are responsible for rapid improvement in respiratory manifestations, including improvement in symptoms and lung function, and reduction in the rate of pulmonary exacerbations. The impact of HEMT on extrapulmonary manifestations of CF is less well established, although significant weight gain and improvement in quality of life have been demonstrated. Recent clinical trials and real-world studies suggest that benefits of HEMT could even prove greater when used earlier in life (i.e., in younger children and infants). This article shortly reviews the past 10 years of development and use of CFTR modulators. Effects of HEMT on extrapulmonary manifestations and on CF demographics are also discussed.<\/jats:p>","DOI":"10.1055\/s-0042-1758851","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T01:12:54Z","timestamp":1671498774000},"page":"186-195","source":"Crossref","is-referenced-by-count":40,"title":["CFTR Modulators: Current Status and Evolving Knowledge"],"prefix":"10.1055","volume":"44","author":[{"given":"Lucile","family":"Regard","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and French Cystic Fibrosis National Reference Center, H\u00f4pital Cochin, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"},{"name":"Institut Cochin and Universit\u00e9 de Paris, INSERM U1016, Paris, France"},{"name":"ERN Lung Cystic Fibrosis Network, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and French Cystic Fibrosis National Reference Center, H\u00f4pital Cochin, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"},{"name":"Institut Cochin and Universit\u00e9 de Paris, INSERM U1016, Paris, France"},{"name":"ERN Lung Cystic Fibrosis Network, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Da Silva","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and French Cystic Fibrosis National Reference Center, H\u00f4pital Cochin, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"},{"name":"ERN Lung Cystic Fibrosis Network, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and French Cystic Fibrosis National Reference Center, H\u00f4pital Cochin, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"},{"name":"Institut Cochin and Universit\u00e9 de Paris, INSERM U1016, Paris, France"},{"name":"ERN Lung Cystic Fibrosis Network, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.lpm.2017.04.012","article-title":"The changing epidemiology and demography of cystic fibrosis","volume":"46","author":"A L Stephenson","year":"2017","journal-title":"Presse Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"M Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"J S Elborn","year":"2016","journal-title":"Lancet"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"S C Bell","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations","volume":"27","author":"G Veit","year":"2016","journal-title":"Mol Biol Cell"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1164\/rccm.201009-1478CI","article-title":"Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life","volume":"183","author":"M Cohen-Cymberknoh","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/17476348.2019.1552832","article-title":"Acute and chronic non-pulmonary complications in adults with cystic fibrosis","volume":"13","author":"L Regard","year":"2019","journal-title":"Expert Rev Respir Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/j.lpm.2017.01.024","article-title":"New treatments targeting the basic defects in cystic fibrosis","volume":"46","author":"I Fajac","year":"2017","journal-title":"Presse Med"},{"issue":"44","key":"ref9","doi-asserted-by":"crossref","first-page":"36639","DOI":"10.1074\/jbc.M112.393637","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner","volume":"287","author":"P D Eckford","year":"2012","journal-title":"J Biol Chem"},{"issue":"21","key":"ref10","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa0909825","article-title":"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation","volume":"363","author":"F J Accurso","year":"2010","journal-title":"N Engl J Med"},{"issue":"07","key":"ref11","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nchembio.1253","article-title":"Mechanism-based corrector combination restores \u0394F508-CFTR folding and function","volume":"9","author":"T Okiyoneda","year":"2013","journal-title":"Nat Chem Biol"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"C E Wainwright","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"ref13","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"J L Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"ref14","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"S M Rowe","year":"2017","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"H GM Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"ref16","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"P G Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"17","key":"ref17","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"D Keating","year":"2018","journal-title":"N Engl J Med"},{"issue":"09","key":"ref18","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"P J Barry","year":"2021","journal-title":"N Engl J Med"},{"issue":"07","key":"ref19","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial","volume":"2","author":"M P Boyle","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"06","key":"ref20","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jcf.2020.04.015","article-title":"Tezacaftor\/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations","volume":"19","author":"A Munck","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"18","key":"ref21","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"B W Ramsey","year":"2011","journal-title":"N Engl J Med"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"S M Rowe","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"ref23","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation","volume":"187","author":"J C Davies","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jcf.2014.09.005","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation","volume":"13","author":"K De Boeck","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"07","key":"ref25","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(15)00201-5","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial","volume":"3","author":"R B Moss","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"03","key":"ref26","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1378\/chest.11-2672","article-title":"Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation","volume":"142","author":"P A Flume","year":"2012","journal-title":"Chest"},{"issue":"06","key":"ref27","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jcf.2013.05.006","article-title":"Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation","volume":"12","author":"H Hebestreit","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jcf.2015.01.008","article-title":"Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States","volume":"15","author":"J Taylor-Cousar","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"02","key":"ref29","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s41030-021-00158-5","article-title":"Real-world long-term ivacaftor for cystic fibrosis in France: clinical effectiveness and healthcare resource utilization","volume":"7","author":"D Hubert","year":"2021","journal-title":"Pulm Ther"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jcf.2017.07.001","article-title":"Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2years of treatment with ivacaftor in a real-world setting","volume":"17","author":"D Hubert","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"N Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"02","key":"ref32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1513\/AnnalsATS.201802-149OC","article-title":"Longitudinal trends in real-world outcomes after initiation of ivacaftor. a cohort study from the cystic fibrosis registry of Ireland","volume":"16","author":"L Kirwan","year":"2019","journal-title":"Ann Am Thorac Soc"},{"issue":"03","key":"ref33","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jcf.2017.03.003","article-title":"Real-life initiation of lumacaftor\/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease","volume":"16","author":"D Hubert","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"02","key":"ref34","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1164\/rccm.201906-1227OC","article-title":"Real-life safety and effectiveness of lumacaftor-ivacaftor in patients with cystic fibrosis","volume":"201","author":"P R Burgel","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"02","key":"ref35","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jcf.2017.09.012","article-title":"Lumacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR","volume":"17","author":"J L Taylor-Cousar","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jcf.2020.06.001","article-title":"Tezacaftor\/ivacaftor in people with cystic fibrosis who stopped lumacaftor\/ivacaftor due to respiratory adverse events","volume":"20","author":"C Schwarz","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"02","key":"ref37","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jcf.2020.06.012","article-title":"Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function","volume":"20","author":"P R Burgel","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"02","key":"ref38","first-page":"00082","article-title":"Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles","volume":"5","author":"J L Taylor-Cousar","year":"2019","journal-title":"ERJ Open Res"},{"issue":"03","key":"ref39","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: interim results of an open-label phase 3 clinical trial","volume":"203","author":"M Griese","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"03","key":"ref40","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"S Sutharsan","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"01","key":"ref41","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"P R Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"03","key":"ref42","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jcf.2022.01.012","article-title":"Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis","volume":"21","author":"C Martin","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"05","key":"ref43","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"D P Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"05","key":"ref44","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1164\/rccm.202008-3177OC","article-title":"Ivacaftor in infants aged 4 to <12 months with cystic fibrosis and a gating mutation. results of a two-part phase 3 clinical trial","volume":"203","author":"J C Davies","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"07","key":"ref45","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study","volume":"6","author":"M Rosenfeld","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"05","key":"ref46","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jcf.2019.06.009","article-title":"A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis","volume":"18","author":"S Walker","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"06","key":"ref47","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jcf.2019.03.009","article-title":"An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB)","volume":"18","author":"M Rosenfeld","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"12","key":"ref48","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del Allele","volume":"203","author":"E T Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"ref49","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for f508del and a minimal function mutation: a phase 3B, randomized, placebo-controlled study","volume":"206","author":"M A Mall","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"06","key":"ref50","doi-asserted-by":"crossref","first-page":"2100908","DOI":"10.1183\/13993003.00908-2021","article-title":"Theratyping cystic fibrosis in vitro in ALI culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells","volume":"58","author":"G Sette","year":"2021","journal-title":"Eur Respir J"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.jcf.2017.06.011","article-title":"Pancreatic insufficiency in cystic fibrosis","volume":"16","author":"V K Singh","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"08","key":"ref52","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1002\/ppul.24353","article-title":"Time for a gut check: pancreatic sufficiency resulting from CFTR modulator use","volume":"54","author":"R Megalaa","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"12","key":"ref53","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/ppul.25065","article-title":"Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor","volume":"55","author":"D Munce","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"02","key":"ref54","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jcf.2021.08.032","article-title":"Restoration of exocrine pancreatic function in child with lumacaftor\/ivacaftor therapy in cystic fibrosis","volume":"21","author":"J Crowley","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"03","key":"ref55","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/MPG.0000000000001788","article-title":"Reduction of recurrence risk of pancreatitis in cystic fibrosis with ivacaftor: case series","volume":"66","author":"A Carrion","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"12","key":"ref56","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.14309\/ajg.0000000000001527","article-title":"Cystic fibrosis transmembrane conductance regulator modulator use is associated with reduced pancreatitis hospitalizations in patients with cystic fibrosis","volume":"116","author":"M L Ramsey","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"04","key":"ref57","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jcf.2021.09.010","article-title":"CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis","volume":"21","author":"M J Gould","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"06","key":"ref58","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/pedi.12026","article-title":"Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study","volume":"14","author":"M D Bellin","year":"2013","journal-title":"Pediatr Diabetes"},{"issue":"05","key":"ref59","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1164\/rccm.201405-0882LE","article-title":"Resolution of cystic fibrosis-related diabetes with ivacaftor therapy","volume":"190","author":"D Hayes Jr","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"05","key":"ref60","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jcf.2020.03.002","article-title":"Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients","volume":"19","author":"B Misgault","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"06","key":"ref61","doi-asserted-by":"crossref","first-page":"107845","DOI":"10.1016\/j.jdiacomp.2020.107845","article-title":"Effect of CFTR modulator therapy on cystic fibrosis-related diabetes","volume":"35","author":"H Gaines","year":"2021","journal-title":"J Diabetes Complications"},{"issue":"02","key":"ref62","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"K J Scully","year":"2022","journal-title":"J Cyst Fibros"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"852551","DOI":"10.3389\/fped.2022.852551","article-title":"Short-term effects of elexacaftor\/tezacaftor\/ivacaftor combination on glucose tolerance in young people with cystic fibrosis-an observational pilot study","volume":"10","author":"I Korten","year":"2022","journal-title":"Front Pediatr"},{"issue":"01","key":"ref64","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/coa.12310","article-title":"Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation","volume":"40","author":"S I Sheikh","year":"2015","journal-title":"Clin Otolaryngol"},{"issue":"02","key":"ref65","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/alr.22716","article-title":"Impact of novel CFTR modulator on sinonasal quality of life in adult patients with cystic fibrosis","volume":"11","author":"J E Douglas","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"issue":"03","key":"ref66","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jcf.2020.07.002","article-title":"Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis","volume":"20","author":"E DiMango","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"05","key":"ref67","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/alr.22722","article-title":"Machine learning evaluates improvement in sinus computed tomography opacification with CFTR modulator therapy","volume":"11","author":"D M Beswick","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"issue":"05","key":"ref68","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jcf.2022.03.002","article-title":"Elexacaftor-tezacaftor-ivacaftor improves sinonasal outcomes in cystic fibrosis","volume":"21","author":"A L Stapleton","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"07","key":"ref69","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jand.2020.03.014","article-title":"Effect of CFTR modulators on anthropometric parameters in individuals with cystic fibrosis: an evidence analysis center systematic review","volume":"121","author":"J Bailey","year":"2021","journal-title":"J Acad Nutr Diet"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"111124","DOI":"10.1016\/j.nut.2020.111124","article-title":"Body composition and weight changes after ivacaftor treatment in adults with cystic fibrosis carrying the G551 D cystic fibrosis transmembrane conductance regulator mutation: a double-blind, placebo-controlled, randomized, crossover study with open-label extension","volume":"85","author":"S J King","year":"2021","journal-title":"Nutrition"},{"issue":"01","key":"ref71","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jcf.2021.05.002","article-title":"Overweight and obesity in adults with cystic fibrosis: an Italian multicenter cohort study","volume":"21","author":"A Gramegna","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"01","key":"ref72","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jcf.2019.12.002","article-title":"Nutritional excess in cystic fibrosis: the skinny on obesity","volume":"19","author":"M Litvin","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"09","key":"ref73","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.3390\/nu13092907","article-title":"The impact of highly effective CFTR modulators on growth and nutrition status","volume":"13","author":"R Bass","year":"2021","journal-title":"Nutrients"},{"issue":"08","key":"ref74","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thoraxjnl-2017-210394","article-title":"Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor","volume":"73","author":"L Bessonova","year":"2018","journal-title":"Thorax"},{"issue":"02","key":"ref75","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jcf.2021.07.018","article-title":"Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR","volume":"21","author":"D Drummond","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"12","key":"ref76","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4254\/wjh.v11.i12.761","article-title":"Lumacaftor\/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients","volume":"11","author":"K Kutney","year":"2019","journal-title":"World J Hepatol"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"102239","DOI":"10.1016\/j.coph.2022.102239","article-title":"Current state of CFTR modulators for treatment of cystic fibrosis","volume":"65","author":"K A Despotes","year":"2022","journal-title":"Curr Opin Pharmacol"},{"issue":"04","key":"ref78","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jcf.2020.02.018","article-title":"Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators \u2013 an international survey","volume":"19","author":"E F Nash","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"03","key":"ref79","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","article-title":"Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation","volume":"20","author":"J L Taylor-Cousar","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"05","key":"ref80","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"C N Fortner","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"02","key":"ref81","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1513\/AnnalsATS.201609-689OC","article-title":"Lumacaftor\/ivacaftor treatment of patients with cystic fibrosis heterozygous for F508del-CFTR","volume":"14","author":"S M Rowe","year":"2017","journal-title":"Ann Am Thorac Soc"},{"issue":"02","key":"ref82","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study","volume":"5","author":"M W Konstan","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"05","key":"ref83","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1164\/rccm.200505-840OE","article-title":"Cystic fibrosis since 1938","volume":"173","author":"P B Davis","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"02","key":"ref84","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jcf.2015.09.002","article-title":"Causes of death in French cystic fibrosis patients: the need for improvement in transplantation referral strategies!","volume":"15","author":"C Martin","year":"2016","journal-title":"J Cyst Fibros"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219086","article-title":"Beyond borders: cystic fibrosis survival between Australia, Canada, France and New Zealand","author":"A Coriati","year":"2022","journal-title":"Thorax"},{"issue":"12","key":"ref86","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1164\/rccm.201303-0429OC","article-title":"Survival benefit of lung transplant for cystic fibrosis since lung allocation score implementation","volume":"187","author":"G Thabut","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"01","key":"ref87","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1183\/09031936.00196314","article-title":"Future trends in cystic fibrosis demography in 34 European countries","volume":"46","author":"P R Burgel","year":"2015","journal-title":"Eur Respir J"},{"issue":"02","key":"ref88","doi-asserted-by":"crossref","first-page":"1700763","DOI":"10.1183\/13993003.00763-2017","article-title":"Modelling future trends in cystic fibrosis demography using the French Cystic Fibrosis Registry: update and sensitivity analysis","volume":"50","author":"P R Burgel","year":"2017","journal-title":"Eur Respir J"},{"issue":"05","key":"ref89","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1164\/rccm.202109-2121LE","article-title":"Major decrease in lung transplantation for patients with cystic fibrosis in France","volume":"205","author":"C Martin","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.07.004","article-title":"The changing epidemiology of cystic fibrosis: the implications for adult care","author":"P R Burgel","year":"2022","journal-title":"Chest"},{"issue":"10","key":"ref91","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.3390\/cells10102793","article-title":"Therapeutic approaches for patients with cystic fibrosis not eligible for current CFTR modulators","volume":"10","author":"I Fajac","year":"2021","journal-title":"Cells"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1758851.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T08:21:13Z","timestamp":1701591673000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1758851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":91,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2023,3,9]]},"published-print":{"date-parts":[[2023,4]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1758851","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,19]]}}}